Se desconocen los efectos de la ezetimiba sobre el embarazo y la lactancia. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolaemia. Eur Heart J ; Ballantyne CM et al.

Author:Akinokinos Tojakasa
Language:English (Spanish)
Genre:Personal Growth
Published (Last):16 September 2019
PDF File Size:20.39 Mb
ePub File Size:3.57 Mb
Price:Free* [*Free Regsitration Required]

The Mechanism of Action of Ezetimibe Zetia on the Inhibition of Cholesterol Absorption Summary: Ezetimibe Zetia is useful in treating LDL-C as either monotherapy, in combination with statins, in combination with fenofibrate, in patients with homozygous familial hypercholesterolemia on either atorvastatin or simvastatin and in patients with homozygous sitosterolemia. Therefore, there is a reduction in the amount of Apo-B48 containing lipoproteins available to go into circulation.

Editor-in-Chief: Anthony J. Nuzum, PharmD, BCACP, CDE Last Reviewed: October Explanation Ezetimibe Zetia is the first cholesterol absorption inhibitor that can primarily reduce low density lipoprotein cholesterol LDL-C , either as monotherapy, in combination with HMG CoA reductase inhibitor statin therapy, in combination with fenofibrate, or in patients with homozygous familial hypercholesterolemia on either atorvastatin or simvastatin and in patients with homozygous sitosterolemia.

It is first critical to understand the basic steps involved for both dietary and biliary cholesterol in the small intestine. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. Effect of ezetimibe coadministered with atorvastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.

Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. North Wales, PA. May Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Edcuation Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Inhibition of intestinal cholesterol absorption by ezetimibe in humans.

The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. Localization and role of NPC1L1 in cholesterol absorption in human intestine.

Chang TY, Chang C. Membrane topology of human NPC1L1, a key protein in enterohepatic cholesterol absorption. Lipoprotein metabolism and vascular biology. In: Therapeutic Lipidology. Human Press. Totowa, NJ.



Kazralrajas Interventions Patients were assigned ezetimine a hour infusion of levosimendan 0. Evangelizacion Indigena en Cuba Similarly, the microspheroids are spherical to sub-spherical, and occur as isolated elements or aggregates forming series of chains of parallel-packed light lamina mm thick. Pharmaco-economics of levosimendan in cardiology: Mechanistic and proof-of-concept studies are still required to clarify the ezetimibd mechanisms involved, while properly designed clinical trials are warranted to translate preclinical or early-phase clinical data into more robust clinical evidence. Scope of this study is to determine whether longer infusion patterns without the hypotension-inducing loading dose could justify an effective and safe alternative approach. All inodilators increased RV ejection fraction, preload recruitable stroke work, and ventricular-vascular coupling without jeopardizing perfusion pressure. Acute kidney injury AKI occurs frequently after cardiac surgery. To describe the frequency of adverse drugs events ADEs as possible causes of mecaniwmo of drugs not included in national essential Medicines list in Colombia.


Ezetimibe therapy: mechanism of action and clinical update

This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. This article has been cited by other articles in PMC. Abstract The lowering of low-density lipoprotein cholesterol LDL-C is the primary target of therapy in the primary and secondary prevention of cardiovascular events. Although statin therapy is the mainstay for LDL-C lowering, a significant percentage of patients prescribed these agents either do not achieve targets with statin therapy alone or have partial or complete intolerance to them. For such patients, the use of adjuvant therapy capable of providing incremental LDL-C reduction is advised. One such agent is ezetimibe, a cholesterol absorption inhibitor that targets uptake at the jejunal enterocyte brush border.





Related Articles